Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma
previously considered to have a poor prognosis. Large gains were made in the first decade …

Purpose To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA)
guideline on antimicrobial prophylaxis for adult patients with immunosuppression …

Background Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as
monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21 …

Background Mantle-cell lymphoma is generally incurable. Despite high rates of complete
response after initial immunochemotherapy followed by autologous stem-cell …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy and
represents 5%–7% of malignant lymphoma in Western Europe. The annual incidence of this …

Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most
commonly treated with combination chemo-immunotherapy at diagnosis because of the …

Abstract Disease Overview Mantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma
characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a …

Background Mantle-cell lymphoma is generally incurable. Initial treatment is not
standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an …